{"entity":{"id":"nct05740566","kind":"trial","name":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Amgen in small-cell lung cancer, active.","summary":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05740566 by Amgen, with 509 participants enrolled, started 2023-05-31. Conditions listed: Small Cell Lung Cancer (SCLC). Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05740566","url":"https://clinicaltrials.gov/study/NCT05740566"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["amrubicin"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05740566","phase":"3","setting":"A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy","sponsor":"Amgen","enrolled":509,"outcomes":[]},"route":"/trials/nct05740566/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}